Predicting longer-term progression-free survival (PFS) with durvalumab after chemoradiotherapy (CRT) in unresectable stage III NSCLC using a mixture cure model (MCM)

被引：1
|
作者：
Faivre-Finn, C. [1 ,2 ]
Jackson, D. [3 ]
Abrams, K. R. [4 ]
Hawkins, N. S. [5 ]
Thiyagarajah, P. [3 ]
Zhang, Y. [6 ]
Hettle, R. [3 ]
Dunlop, W. [3 ]
Spigel, D. R. [7 ]
机构：
[1] Univ Manchester, Manchester, Lancs, England
[2] Christie NHS Fdn Trust, Manchester, Lancs, England
[3] AstraZeneca, Cambridge, England
[4] Univ Warwick, Dept Stat, Coventry, W Midlands, England
[5] Univ Glasgow, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland
[6] AstraZeneca, Gaithersburg, MD USA
[7] Sarah Cannon Res Inst Tennessee Oncol, Med Oncol, Nashville, TN USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.10.102
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
84P
引用
收藏
页码：S1408 / S1409
页数：2
相关论文
共 30 条
  • [1] PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
    Girard, N.
    Smit, H. J. M.
    Sibille, A.
    McDonald, F.
    Mornex, F.
    Garassino, M. C. C.
    Filippi, A. R.
    Peters, S.
    Field, J. K.
    Christoph, D. C.
    Fietkau, R.
    Haakensen, V. D.
    Bar, J.
    Chouaid, C.
    Bray, V.
    Kao, S.
    Sawyer, W.
    Allen, A.
    Licour, M.
    Garrido, P.
    ANNALS OF ONCOLOGY, 2021, 32 : S939 - S940
  • [2] Pacific-R Real-World Study: Treatment Duration and Interim Analysis of Progression-Free Survival in Unresectable Stage III NSCLC Patients Treated with Durvalumab After Chemoradiotherapy
    Christoph, Daniel
    Girard, N.
    Smit, H. J. M.
    Sibille, A.
    Mcdonald, F.
    Mornex, F.
    Garassino, M. C.
    Filippi, A. R.
    Peters, S.
    Field, J. K.
    Haakensen, V. Drageset
    Bar, J.
    Chouaid, C.
    Bray, V.
    Kao, S.
    Sawyer, W.
    Allen, A.
    Licour, M.
    Garrido, P.
    Fietkau, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 151 - 151
  • [3] Pacific-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with Durvalumab after chemoradiotherapy
    Christoph, D. C.
    Girard, N.
    Smit, H. J. M.
    Sibille, A.
    McDonald, F.
    Mornex, F.
    Garassino, M. C.
    Filippi, A. R.
    Peters, S.
    Field, J. K.
    Haakensen, Drageset, V
    Bar, J.
    Chouaid, C.
    Bray, V
    Kao, S.
    Sawyer, W.
    Allen, A.
    Licour, M.
    Garrido, P.
    Fietkau, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 53 - 53
  • [4] Real-world outcomes with durvalumab (durva) after chemoradiotherapy (CRT) in patients with unresectable stage III NSCLC (SPOTLIGHT)
    Mooradian, M.
    Allen, A.
    Cai, L.
    Xiao, Y.
    Chander, P.
    ANNALS OF ONCOLOGY, 2022, 33 : S86 - S86
  • [5] Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study
    Girard, Nicolas
    Bar, Jair
    Garrido, Pilar
    Garassino, Marina C.
    McDonald, Fiona
    Mornex, Francoise
    Filippi, Andrea R.
    Smit, Hans J. M.
    Peters, Solange
    Field, John K.
    Christoph, Daniel C.
    Sibille, Anne
    Fietkau, Rainer
    Haakensen, Vilde D.
    Chouaid, Christos
    Markman, Ben
    Hiltermann, T. Jeroen N.
    Taus, Alvaro
    Sawyer, William
    Allen, Allison
    Chander, Pratibha
    Licour, Muriel
    Solomon, Benjamin
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (02) : 181 - 193
  • [6] Elevated neutrophil-to-lymphocyte ratio (NLR) is associated with poorer progression-free survival in unresectable stage III NSCLC treated with consolidation durvalumab
    Nindra, Udit
    Shahnam, Adel
    Stevens, Samuel
    Pal, Abhijit
    Nagrial, Adnan
    Lee, Jenny
    Yip, Po Yee
    Adam, Tamiem
    Boyer, Michael
    Kao, Steven
    Bray, Victoria
    THORACIC CANCER, 2022, 13 (21) : 3058 - 3062
  • [7] Durvalumab after Chemoradiotherapy (CRT) in Unresectable Stage III NSCLC. Comparative Study of Two Cohorts in the Real-World Setting
    Tavara, B.
    Rojas, M.
    Rodriguez, Z.
    Garrido, M. L.
    Lopez, L.
    Medina, S.
    Ponte, C.
    Lopez, A.
    Sanchez, E.
    Pedraza, M.
    Vinals, P.
    Lopez, M.
    Alonso, D.
    Rodriguez, A.
    Castanon, C.
    Davila, E.
    De Sande, L. M.
    Nieto, B.
    Vallejo Pascual, M. E.
    Rodriguez, J. D. L. R.
    Garcia Palomo, A.
    Diz Tain, P.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S283 - S284
  • [8] 5-Year Survival Data of Durvalumab after Chemoradiotherapy for unresectable Stage III NSCLC - an Update from the PACIFIC Study
    de Wit, M.
    Spigel, D.
    Faivre-Finn, C.
    Gray, J.
    Vicente, D.
    Planchard, D.
    Paz-Ares, L.
    Vansteenkiste, J.
    Garassino, M.
    Hui, R.
    Quantin, X.
    Rimner, A.
    Wu, Y. -L.
    Ozguroglu, M.
    Lee, K. H.
    Kato, T.
    Macpherson, E.
    Newton, M.
    Thiyagarajah, P.
    Antonia, S.
    Reck, M.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2021, 197 (SUPPL 1) : S8 - S9
  • [9] SPOTLIGHT real-world study: Outcomes with or without consolidation durvalumab (D) after chemoradiotherapy (CRT) in patients with unresectable stage III NSCLC
    Whitaker, R. M.
    Cai, L.
    Wang, A.
    Qiao, Y.
    Chander, P.
    Mooradian, M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S111 - S111
  • [10] 5-year survival outcomes with durvalumab after chemoradiotherapy in unresectable Stage III NSCLC - an update from the PACIFIC trial
    de Wit, M.
    Spigel, D. R.
    Faivre-Finn, C.
    Gray, J. E.
    Vicente, D.
    Planchard, D.
    Paz-Ares, L.
    Vansteenkiste, J. F.
    Garassino, M. C.
    Hui, R.
    Quantin, X.
    Rimner, A.
    Wu, Y. -L
    Oezgueroglu, M.
    Lee, K. H.
    Kato, T.
    Macpherson, E.
    Newton, M.
    Thiyagarajah, P.
    Antonia, S. J.
    Reck, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 109 - 110
123